Hasil Pencarian  ::  Simpan CSV :: Kembali

"Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder associated with significant morbidity and mortality. Patients with this illness are prone to sudden death, angina, syncope, and heart failure. Symptomatic patients with HOCM are usually medically treated; in the few patients with persistent symptoms, surgical myomectomy offers satisfactory control.1'1 The role of DDD pacing in effort to reduce left ventricular outflow tract (LVOT) gradient is still controversial.3-4 Recently, non-surgical septal reduction therapy (NSRT) has gained popularity as an alternative to surgery, because the procedure is much simpler, safe and effective for relief of symptoms of LVOT obstruction.5 7This paper will report a case of HOCM successfully treated with NSRT."

"Latar Belakang: Kompleks prematur ventrikel (KVP) dikaitkan dengan risiko penurunan fungsi ventrikel dan gagal jantung, dan meningkatkan mortalitas jangka panjang. Variasi sirkadian yang rendah merupakan salah satu prediktor terjadinya kardiomiopati yang diinduksi oleh KVP. KVP idiopatik tipe independen merupakan salah satu bentuk dari KVP dengan gambaran distribusi variasi sirkadian yang rendah. Namun tidak semua KVP independen memiliki variasi sirkadian yang rendah. Belum ada studi yang menilai perbedaan fungsi sistolik intrinsik VKi menggunakan global longitudinal strain (GLS) pada KVP idiopatik independen dengan KVP idiopatik non-independen.Tujuan: Mengetahui hubungan antara kompleks ventrikel prematur idiopatik tipe independen dengan GLS ventrikel kiri melalui ekokardiografi speckle tracking pada pasien tanpa penyakit jantung struktural.Metode: Penelitian ini merupakan studi potong lintang dengan menggunakan data pasien aritmia ventrikel idiopatik yang dikumpulkan di RSPJD Harapan Kita Jakarta pada bulan Februari 2021- Mei 2021. Evaluasi KVP idiopatik dilakukan dengan EKG 12 sandapan, pemeriksaan Holter monitoring 24 jam. Data dasar ekokardiografi diambil dan penilaian fungsi sistolik intrinsik ventrikel kiri (Vki) dilakukan menggunakan ekokardiografi speckle tracking dengan global longitudinal study (GLS).Hasil: Dari 67 pasien KVP idiopatik yang disertakan dalam penelitian, didapatkan sebesar 27 pasien (40,2%) dengan KVP tipe independen dan 40 pasien (59,8%) dengan KVP non-independen. Sebanyak 31 (46,3%) pasien memiliki disfungsi sistolik ventrikel kiri pada pemeriksaan GLS (kurang dari -18). KVP tipe independen (OR 5,3; IK 95% 1,10-33,29; p = 0,038), beban KVP 9% (OR 16; IK 95% 1,58-163,61; p = 0,019), jenis kelamin laki-laki (OR 6,58; IK 95% 0,80-0,99; p = 0,029), dan episode TV non-sustained (OR 13,88; IK 95% 1,77-108,53; p = 0,012) berhubungan secara signifikan dengan penurunan fungsi sistolik intrinsik Vki.Kesimpulan: Kompleks ventrikel prematur idiopatik tipe independen berhubungan dengan penurunan sistolik intrinsik ventrikel kiri melalui ekokardiografi speckle tracking. Evaluasi tipe KVP idiopatik perlu dilakukan karena berhubungan dengan prognosis pasien dalam praktik klinis.

---

Background: Premature ventricular complexes (PVC) was associated with a risk of decreased ventricular function and heart failure, and increased long-term mortality. Low circadian variation is one of the predictors of PVC-induced cardiomyopathy. Independent-type-PVC (I-PVC) is a form of PVC with a low distribution of circadian variation. However, not all I-PVC show low circadian variation. No studies have been performed to examine differences in intrinsic systolic function of left ventricle (LV) using global longitudinal strain (GLS) in independent versus non-independent idiopathic PVC.

Objective: To determine the relationship between I-PVC and intrinsic systolic function of LV using speckle tracking echocardiography in patients without structural heart disease.

Methods: A cross-sectional study was conducted using data from patients with idiopathic ventricular arrhythmias collected at RSPJD Harapan Kita Jakarta in February 2021-May 2021. Evaluation of idiopathic PVC was carried out using a 12-lead ECG, 24-hour Holter monitoring. Basic echocardiography was performed then LV intrinsic systolic function was assessed using speckle tracking echocardiography with global longitudinal study (GLS).

Results: Of the 67 patients with idiopathic PVC included in the study, 27 (40.2%) patients included in independent PVC group and 40 (59.8%) patients in non-independent PVC group. A total of 31 (46.3%) patients had LV systolic dysfunction on GLS examination (less than -18). Independent-type-PVC (OR 5.3; 95% CI 1.10-33.29; p = 0.038), PVC burden of 9% (OR 16; 95% CI 1.58-163.61; p = 0.019), male gender (OR 6.58; 95% CI 0.80-0.99; p = 0.029), and non-sustained VT episodes (OR 13.88; 95% CI 1.77-108.53; p = 0.012) was significantly associated with a decrease in LV intrinsic systolic function.

Conclusion: Independent-type-PVC was associated with decreased in LV intrinsic systolic function assessed by speckle tracking echocardiography. Evaluation of the type of idiopathic PVC needs to be considered since it is related with patient's prognosis in clinical practice."

"Latar Belakang: Salah satu penyebab kematian pada pasien penyakit ginjal kronis adalah gangguan kardiovaskular. Adanya hipertrofi pada ventrikel kiri dijadikan surrogate marker kondisi kardiomiopatik dan progresivitas penyakit ginjal kronis. Penelitian terbaru menunjukkan adanya peran FGF23 dalam menstimulasi terjadinya hipertrofi jantung dan meningkatkan aktivitas sistem renin-angiotensin-aldosteron serta berfungsi sebagai faktor parakrin dengan peran dalam remodelling jantung.Metode: Penelitian ini dilakukan dengan menggunakan tikus model nefrektomi 5/6 yang diberikan terapi irbesartan, simvastatin dan kombinasi keduanya selama satu bulan. Tekanan darah diukur pada saat sebelum dan sesudah pemberian obat. Tikus kemudian ditempatkan pada kandang metabolik selama 24 jam untuk pengambilan urin. Nekropsi dilakukan untuk mengambil darah dan jantung. Pemeriksaan yang dilakukan antara lain pemeriksaan indeks massa ventrikel kiri jantung, volume dan kadar protein dalam urin, kadar urea dan kreatinin dalam serum, serta kadar FGF23 dan hormon PTH dalam serum.Hasil: Hasil dari pemeriksaan tersebut menunjukkan bahwa penggunaan irbesartan dapat menurunkan tekanan darah dan indeks massa ventrikel kiri secara signifikan. Penggunaan irbesartan, simvastatin dan kombinasi keduanya tidak menunjukkan penurunan yang signifikan terhadap hasil pemeriksaan fungsi ginjal, kadar hemoglobin, indeks massa ventrikel kiri, FGF23 dan hormon paratiroid.Kesimpulan: Dari hasil penelitian ini, dapat disimpulkan bahwa baik penggunaan irbesartan, simvastatin, maupun keduanya memiliki kecenderungan untuk mengurangi kejadian kardiomiopatik uremik pada tikus model nefrektomi 5/6

---

Introduction: Cardiovascular events is one of the causes of chronic renal disease’s mortality. Left ventricular hypertrophy was a surrogate marker for cardiomyopathy and progressivity of chronic renal disease. Latest study mentioned about the role of FGF23 on stimulating cardiac hypertrophy and renin-angiotensin-aldosterone activity and also a paracrine factor of cardiac remodeling.

Methods: This study was done using 5/6 nephrectomy rats getting irbesartan, simvastatin and combination of both treatments for 30 days. Blood pressure was measured before and after the treatment. Urine sample was collected for 24 hours for protein assay. Sacrificing the animals was done at the end of study to harvest the heart and blood sample. Heart sample was weighed and measured for left ventricle mass index. Blood sample was used for hemoglobin assay. Serum sample was used for urea, creatinine, FGF23 and PTH assay.

Result: Irbesartan significantly lowered the blood pressure and cardiac mass index, but not significantly improved renal function, hemoglobin level, left ventricular mass index, FGF23 and PTH hormone. Simvastatin and combination of both treatments did not significantly improve renal function, hemoglobin level, left ventricular mass index, FGF23 and PTH hormone.

Conclusion: The use of irbesartan, simvastatin and both combinations tend to improve uremic cardiomyopathy condition on 5/6 nephrectomy rats’ heart."

"Latar belakang. Gagal ginjal terminal (GGT) atau penyakit ginjal kronik (PGK) stadium 5 merupakan masalah serius pada populasi anak dan dewasa, dengan insidens dan prevalensnya yang terus meningkat setiap tahun dan dapat menyebabkan komplikasi penyakit kardiovaskular. Kardiomiopati dilatasi (KMD) merupakan salah satu penyakit kardiovaskular yang dapat menyebabkan kematian pada anak dengan GGT. Prevalens KMD pada anak GGT cukup bervariasi, antara 2- 41%. Namun, saat ini studi tentang kejadian KMD pada anak GGT di Indonesia masih terbatas, terutama pada anak dengan GGT yang menjalani dialisis. Tujuan. Mengetahui prevalens KMD dan faktor risiko yang berasosiasi dengan kejadian KMD, yaitu etiologi GGT, status nutrisi, anemia, hipertensi dan jenis dialisis pada anak dengan GGT yang menjalani dialisis di Rumah Sakit Cipto Mangunkusumo (RSCM). Metode. Desain studi potong lintang dilakukan di RSCM pada anak dengan GGT yang menjalani dialisis selama periode 2017-2022 yang memenuhi kriteria inklusi dan eksklusi. Pengambilan data dilakukan melalui penelusuran rekam medik. Hasil. Terdapat 126 subjek yang memenuhi kriteria inklusi dan eksklusi dengan jenis kelamin lelaki lebih banyak (59,5%), mayoritas usia di atas 5 tahun (98,4%), dengan median 12 tahun (10-15). Sebanyak 95,2% subjek adalah rujukan dari rumah sakit luar datang pertama kali ke RSCM dengan kegawatdaruratan dan membutuhkan dialisis segera. Prevalens KMD pada studi ini adalah 53,2%. Hasil analisis multivariat dengan regresi logistik menunjukkan anemia dan status nutrisi berasosiasi positif dengan kejadian KMD (OR 4,8, IK 95% 1,480-15,736, p=0,009) ; (OR 9,383, IK 95% 3,644-24,161, p=0,000). Tidak terbukti adanya hubungan etiologi PGK, hipertensi dan jenis dialisis dengan kejadian KMD. Kesimpulan. Prevalens KMD pada anak dengan GGT yang menjalani dialisis di RSCM adalah 53,2%. Terdapat asosiasi positif antara anemia dan status nutrisi dengan kejadian KMD. Etiologi GGT, hipertensi, dan jenis dialisis tidak berasosiasi dengan kejadian KMD pada anak dengan GGT yang menjalani dialisis.  

---

Background.  Kidney failure is a serious problem in children with the incidence and prevalence increasing every year, can cause cardiovascular disease. Dilated cardiomyopathy (DCM) is one of the cardiovascular disease can cause mortality in children with kidney failure. The prevalence varies between 2-44% and limited studies in Indonesia especially in children with kidney failure on dialysis. 

Objective. To determine the prevalence of DCM and risk factors in children with kidney failure on dialysis in Cipto Mangunkusumo hospital. The association of etiology of kidney failure, nutritional status, anemia, hypertention, and type of dialysis with DCM in children with kidney failure. 

Methods. A cross-sectional study among children with kidney failure according to the inclusion and exclusion criteria during 2017-2022 periode, in Cipto Mangunkusumo hospital. Collecting data using medical record. 

Result. There were 126 study subjects, with 59,5% male and 98,4% over 5 years old, the median is 12 years (10-15). The prevalence of DCM was 53.2%. The results of the multivariate analysis showed anemia and nutritional status were associated with the incidence of DCM, (OR 4.8, 95% CI 1.480-15.736, p=0.009); (OR 9.383, 95% CI 3.644-24.161, p= 0.000). There is no association between the etiology of kidney failure, hypertension and type of dialysis with DCM. 

Conclussion. The prevalence of DCM in children with kidney failure on dialysis was 53.2%. Anemia and nutritional status was associated with DCM in children with kidney failure on dialysis. The etiology of kidney failure, hypertension, and type of dialysis were not associated with DCM."

"ABSTRAK Latar belakang: disglikemia adalah keadaan intoleransi glukosa berupa peningkatan kadar gula darah yang berhubungan dengan risiko penyakit kardiovaskular. Seiring dengan waktu, pada akhirnya diabetes akan menimbulkan kerusakan pada target organ, salah satu yang penting adalah pada sistem organ kardiovaskular, dapat berupa penyakit jantung koroner, kardiomiopati diabetes, penyakit serebrovaskuler, dan penyakit arteri perifer. Diabetes juga meningkatkan risiko terjadinya gagal jantung. Pada kardiomiopati diabetes, proses fibrosis yang masih reversibel sudah mulai terjadi bahkan ketika penderita masih asimtomatik. Pemeriksaan baku emas untuk mendeteksi terjadinya fibrosis miokard secara dini adalah pemeriksaan histopatologi jaringan miokardium melalui biopsi. Akan tetapi pemeriksaan ini sangat invasif dan tidak nyaman bagi subjek. Pemeriksaan yang kemudian berkembang adalah pencitraan menggunakan Cardiac Magnetic Resonance Imaging (CMRI). Akan tetapi pemeriksaan ini cukup mahal, dan tidak tersedia pada semua fasilitas kesehatan. Sementara itu, ST2 adalah penanda enzim jantung yang menggambarkan derajat proses fibrosis yang sedang terjadi pada miokard, terutama pada keadaan gagal jantung. Pemeriksaan menggunakan penanda enzim dapat menjadi alternatif dengan keuntungan lebih murah, dapat terjangkau luas dan mudah tersedia. Tujuan: Mengetahui hubungan antara kadar ST2 serum dengan fibrosis miokard interstisial pada penderita disglikemia. Metode: Pasien disglikemia yang lolos kriteria eksklusi berupa komorbid kardiovaskular akan menjalani pemeriksaan kadar ST2 serum dan T1 relaxation time menggunakan Cardiac MRI. Selanjutnya dilakukan analisis hubungan antara kadar ST2 serum dan T1 relaxation time. Hasil penelitian: Sebanyak 34 pasien diikutsertakan ke dalam penelitian ini. Didapatkan kisaran nilai kadar ST2 serum antara 12.40-53.22 ng/dL (median 19.95 ng/dL). Rerata nilai T1 relaxation time didapatkan sebesar 443.39 ± 113.35 ms. Terdapat korelasi bermakna antara kadar ST2 serum dengan fibrosis diffuse miokardium (Spearman correlation r = -0,547, p < 0.01). Pada analisa multivariat hubungan antara kadar ST2 serum dan T1 relaxation time tidak dipengaruhi oleh faktor perancu yang telah ditetapkan (r = -0,44, p = 0,033). Kesimpulan: Hasil penelitian ini menunjukkan kadar ST2 serum berkolerasi dengan fibrosis diffuse miokardium pada populasi disglikemia.ABSTRACT Background: disglycemia is a state of glucose intolerance include increased blood sugar levels associated with risk of cardiovascular disease. Over time, eventually diabetes will cause damage to the target organ, especially the cardiovascular system, which include coronary heart disease, diabetic cardiomyopathy, diabetes, cerebrovascular disease, and peripheral arterial disease. Diabetes also increases the risk of heart failure. The clinical appearance of the disease is wide ranging from asymptomatic to symptomatic heart failure. Gold standard examination to detect the occurrence of early myocardial fibrosis is histopathological examination of myocardial tissue via biopsy. However, these tests are very invasive and uncomfortable for the subject. Examination which later evolved is imaging using cardiac magnetic resonance imaging (CMRI). However, these tests are quite expensive, and not available at all health facilities. Meanwhile, ST2 is a cardiac enzyme marker that describes the degree of fibrosis process in the myocardium, especially in the state of heart failure. Examination using enzyme markers can be a cheaper alternative, widely accessible and readily available. Aim: Knowing the relationship between serum levels of ST2 with myocardial interstitial fibrosis in disglycemic patients. Methods: Disglycemic patients who passed from the exclusion criteria (cardiovascular comorbid), will undergo a serum ST2 levels and T1 relaxation time using cardiac MRI. Then we analyzed the relationship between serum levels of ST2 and T1 relaxation time. Results: A total of 34 patients were included in this study. The range values of serum ST2 levels were between 12.40-53.22 ng/dL (median 19.95 ng/dL). The mean value of T1 relaxation time were 443.39 ± 113.35 ms. There is a significant correlation between serum levels of ST2 with diffuse myocardial fibrosis (Spearman correlation r = -0.547, p <0:01). Multivariate analysis showed the relationship between serum levels of ST2 and T1 relaxation time is not influenced by confounding factors (r = -0.44, p = 0.033). Conclusion: ST2 serum levels correlates with diffuse myocardial fibrosis on disglycemic population.;Background: disglycemia is a state of glucose intolerance include increased blood sugar levels associated with risk of cardiovascular disease. Over time, eventually diabetes will cause damage to the target organ, especially the cardiovascular system, which include coronary heart disease, diabetic cardiomyopathy, diabetes, cerebrovascular disease, and peripheral arterial disease. Diabetes also increases the risk of heart failure. The clinical appearance of the disease is wide ranging from asymptomatic to symptomatic heart failure. Gold standard examination to detect the occurrence of early myocardial fibrosis is histopathological examination of myocardial tissue via biopsy. However, these tests are very invasive and uncomfortable for the subject. Examination which later evolved is imaging using cardiac magnetic resonance imaging (CMRI). However, these tests are quite expensive, and not available at all health facilities. Meanwhile, ST2 is a cardiac enzyme marker that describes the degree of fibrosis process in the myocardium, especially in the state of heart failure. Examination using enzyme markers can be a cheaper alternative, widely accessible and readily available. Aim: Knowing the relationship between serum levels of ST2 with myocardial interstitial fibrosis in disglycemic patients. Methods: Disglycemic patients who passed from the exclusion criteria (cardiovascular comorbid), will undergo a serum ST2 levels and T1 relaxation time using cardiac MRI. Then we analyzed the relationship between serum levels of ST2 and T1 relaxation time. Results: A total of 34 patients were included in this study. The range values of serum ST2 levels were between 12.40-53.22 ng/dL (median 19.95 ng/dL). The mean value of T1 relaxation time were 443.39 ± 113.35 ms. There is a significant correlation between serum levels of ST2 with diffuse myocardial fibrosis (Spearman correlation r = -0.547, p <0:01). Multivariate analysis showed the relationship between serum levels of ST2 and T1 relaxation time is not influenced by confounding factors (r = -0.44, p = 0.033). Conclusion: ST2 serum levels correlates with diffuse myocardial fibrosis on disglycemic population.;Background: disglycemia is a state of glucose intolerance include increased blood sugar levels associated with risk of cardiovascular disease. Over time, eventually diabetes will cause damage to the target organ, especially the cardiovascular system, which include coronary heart disease, diabetic cardiomyopathy, diabetes, cerebrovascular disease, and peripheral arterial disease. Diabetes also increases the risk of heart failure. The clinical appearance of the disease is wide ranging from asymptomatic to symptomatic heart failure. Gold standard examination to detect the occurrence of early myocardial fibrosis is histopathological examination of myocardial tissue via biopsy. However, these tests are very invasive and uncomfortable for the subject. Examination which later evolved is imaging using cardiac magnetic resonance imaging (CMRI). However, these tests are quite expensive, and not available at all health facilities. Meanwhile, ST2 is a cardiac enzyme marker that describes the degree of fibrosis process in the myocardium, especially in the state of heart failure. Examination using enzyme markers can be a cheaper alternative, widely accessible and readily available. Aim: Knowing the relationship between serum levels of ST2 with myocardial interstitial fibrosis in disglycemic patients. Methods: Disglycemic patients who passed from the exclusion criteria (cardiovascular comorbid), will undergo a serum ST2 levels and T1 relaxation time using cardiac MRI. Then we analyzed the relationship between serum levels of ST2 and T1 relaxation time. Results: A total of 34 patients were included in this study. The range values of serum ST2 levels were between 12.40-53.22 ng/dL (median 19.95 ng/dL). The mean value of T1 relaxation time were 443.39 ± 113.35 ms. There is a significant correlation between serum levels of ST2 with diffuse myocardial fibrosis (Spearman correlation r = -0.547, p <0:01). Multivariate analysis showed the relationship between serum levels of ST2 and T1 relaxation time is not influenced by confounding factors (r = -0.44, p = 0.033). Conclusion: ST2 serum levels correlates with diffuse myocardial fibrosis on disglycemic population.;Background: disglycemia is a state of glucose intolerance include increased blood sugar levels associated with risk of cardiovascular disease. Over time, eventually diabetes will cause damage to the target organ, especially the cardiovascular system, which include coronary heart disease, diabetic cardiomyopathy, diabetes, cerebrovascular disease, and peripheral arterial disease. Diabetes also increases the risk of heart failure. The clinical appearance of the disease is wide ranging from asymptomatic to symptomatic heart failure. Gold standard examination to detect the occurrence of early myocardial fibrosis is histopathological examination of myocardial tissue via biopsy. However, these tests are very invasive and uncomfortable for the subject. Examination which later evolved is imaging using cardiac magnetic resonance imaging (CMRI). However, these tests are quite expensive, and not available at all health facilities. Meanwhile, ST2 is a cardiac enzyme marker that describes the degree of fibrosis process in the myocardium, especially in the state of heart failure. Examination using enzyme markers can be a cheaper alternative, widely accessible and readily available. Aim: Knowing the relationship between serum levels of ST2 with myocardial interstitial fibrosis in disglycemic patients. Methods: Disglycemic patients who passed from the exclusion criteria (cardiovascular comorbid), will undergo a serum ST2 levels and T1 relaxation time using cardiac MRI. Then we analyzed the relationship between serum levels of ST2 and T1 relaxation time. Results: A total of 34 patients were included in this study. The range values of serum ST2 levels were between 12.40-53.22 ng/dL (median 19.95 ng/dL). The mean value of T1 relaxation time were 443.39 ± 113.35 ms. There is a significant correlation between serum levels of ST2 with diffuse myocardial fibrosis (Spearman correlation r = -0.547, p <0:01). Multivariate analysis showed the relationship between serum levels of ST2 and T1 relaxation time is not influenced by confounding factors (r = -0.44, p = 0.033). Conclusion: ST2 serum levels correlates with diffuse myocardial fibrosis on disglycemic population."

"Latar Belakang: Diabetes melitus (DM) merupakan penyakit kronik umum yang terjadi pada masyarakat modern. Setelah penyakit jantung dan kanker, penyakit DM mewakili penyebab kematian ketiga pada manusia. Diabetes melitus tipe 2 merupakan jenis yang paling umum dari penyakit DM dan DM tipe 2 dapat menyebabkan komplikasi pada jantung yang disebut sebagai diabetic cardiomyopathy. Metformin adalah obat yang meningkatkan sensivitas terhadap insulin dan banyak digunakan sebagai terapi untuk diabetes melitus tipe 2 namun metformin memiliki berbagai macam efek samping yang merugikan. Maka dari itu diperlukan suatu obat alternatif yang lebih aman untuk terapi diabetes melitus tipe 2 yaitu seperti alfa mangostin karena alfa mangostin memiliki efek antidiabetik dan kardioprotektif. Tujuan dari penelitian ini adalah menganalisa efek terapi alfa mangostin pada tikus dengan diabetic cardiomyopathy.Metode: Hewan percobaan yang digunakan berupa tikus jantan galur wistar. Hewan coba dibagi jadi 6 kelompok yaitu kelompok 1 diberikan pakan normal, kelompok 2 diberikan pakan normal dan senyawa alfa mangostin sebesar 200 mg/kg BB tikus,kelompok 3 diberikan pakan tinggi lemak, kelompok 4 diberikan makanan tinggi lemak dan diberikan suntikan streptozotocin lalu diberikan metformin 200 mg/kg BB tikus, kelompok 5 diberikan makanan tinggi lemak dan diberikan suntikan streptozotocin lalu diberikan alfa mangostin 100 mg/kg BB tikus dan kelompok 6 diberikan makanan tinggi lemak dan diberikan suntikan streptozotocin lalu diberikan alfa mangostin 200 mg/kg BB tikus. Gula darah diukur setiap minggu, tekanan darah dan berat badan dan berat jantung diukur pada minggu saat hewan disacrifice. Semua sampel organ jantung dan plasma dari semua kelompok hewan uji yang telah disacrifice di minggu ke 11 akan dianalisa kadar HOMA-IR, MCP-1, TNF-α, IL-6, IL-1β dan dilakukan pemeriksaan histopatologi.Hasil Penelitian : Pemberian streptozotocin dan diet tinggi lemak menyebabkan gula darah tinggi, tekanan darah tinggi, nilai HOMA-IR tinggi, nilai rasio BB/BJ tinggi, kadar MCP-1, TNF-α, IL-6, IL-1β tinggi dan ukuran sel kardiomiosit besar. Tetapi dengan pemberian metformin dan alfa mangostin dapat merendahkan nilai gula darah , tekanan darah , nilai HOMA-IR, nilai rasio BB/BJ, kadar MCP-1, TNF-α, IL-6, IL-1β.Kesimpulan : Alfa mangostin memperlihatkan efek anti-inflamasi dan antidiabetik terhadap kadar gula darah dan jantung hewan coba yang diberikan diet tinggi lemak dan disuntik STZ.

---

Background : Diabetes mellitus (DM) is a common chronic disease that occurs in modern society. After heart disease and cancer, DM represents the third leading cause of death in humans. Diabetes mellitus type 2 is the most common type of DM disease and type 2 diabetes can cause heart complications called diabetic cardiomyopathy. Metformin is a drug that increases insulin sensitivity and is widely used as a therapy for type 2 diabetes mellitus but metformin has a variety of adverse side effects. Therefore we need a safer alternative drug for the treatment of type 2 diabetes mellitus, such as alpha mangostin because alpha mangostin has antidiabetic and cardioprotective effects. The purpose of this study was to analyze the effects of alpha mangostin therapy in rats with diabetic cardiomyopathy.

Method : Test animals or experimental animals used in the form of male wistar strain rats. Experimental animals were divided into 6 groups: group 1 was given normal food, group 2 was given normal food and alpha mangostin compound was 200 mg / kg BW rat, group 3 was given high fat food, group 4 was given high fat food and given streptozotocin injection and then given metformin 200 mg / kg body weight rat, group 5 given high fat food and given streptozotocin injection then given alpha mangostin 100 mg / kg body weight rat and group 6 given high fat food and given streptozotocin injection then given alpha mangostin 200 mg / kg body rat. Blood sugar is measured every week, blood pressure and body weight and heart weight are measured on the week when the animal is disacrifice. All cardiac organ and plasma samples from all groups of test animals that were sacrificed at week 11 will be analyzed for HOMA-IR, MCP-1, TNF-α, IL-6, IL-1β levels and histopathological examination.

Result : Administration of streptozotocin and high-fat diets causes high blood sugar, high blood pressure, high HOMA-IR values, high BB / BJ ratio values, MCP-1 levels, TNF-α, IL- 6, high IL-1β and large cardiomyocyte cell sizes . But by giving metformin and alpha mangostin can lower blood sugar values, blood pressure, HOMA-IR values, BB / BJ ratio values, MCP-1 levels, TNF-α, IL-6, IL-1β.

Conclusion : Alfa mangostin exhibits anti-inflammatory and antidiabetic effects on blood sugar and heart of experimental animals which are given a high-fat diet and STZ injections."